Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma.
Saved in:
| Title: | Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma. |
|---|---|
| Authors: | Borgers JSW; Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands., van Wesemael TJ; Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands., Gelderman KA; Sanquin Diagnostic Services, Amsterdam, Noord-Holland, Netherlands., Rispens T; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam, Noord-Holland, UK., Verdegaal EME; Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands., Moes DJAR; Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands., Korse CM; Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, Netherlands., Kapiteijn E; Department of Medical Oncology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands., Welters MJP; Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Netherlands., van der Burg SH; Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Netherlands., van Houdt WJ; Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands., van Thienen JV; Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands., Haanen JBAG; Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands j.haanen@nki.nl.; Department of Medical Oncology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands., van der Woude D; Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands. |
| Source: | Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Jun 30; Vol. 12 (6). Date of Electronic Publication: 2024 Jun 30. |
| Publication Type: | Journal Article; Multicenter Study |
| Journal Info: | Publisher: BMJ Publishing Group Ltd Country of Publication: England NLM ID: 101620585 Publication Model: Electronic Cited Medium: Internet ISSN: 2051-1426 (Electronic) Linking ISSN: 20511426 NLM ISO Abbreviation: J Immunother Cancer Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 38945553 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Borgers+JSW%22">Borgers JSW</searchLink>; Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Wesemael+TJ%22">van Wesemael TJ</searchLink>; Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands.<br /><searchLink fieldCode="AU" term="%22Gelderman+KA%22">Gelderman KA</searchLink>; Sanquin Diagnostic Services, Amsterdam, Noord-Holland, Netherlands.<br /><searchLink fieldCode="AU" term="%22Rispens+T%22">Rispens T</searchLink>; Department of Immunopathology, Sanquin Research and Landsteiner Laboratory, Amsterdam, Noord-Holland, UK.<br /><searchLink fieldCode="AU" term="%22Verdegaal+EME%22">Verdegaal EME</searchLink>; Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands.<br /><searchLink fieldCode="AU" term="%22Moes+DJAR%22">Moes DJAR</searchLink>; Clinical Pharmacy and Toxicology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands.<br /><searchLink fieldCode="AU" term="%22Korse+CM%22">Korse CM</searchLink>; Laboratory Medicine, Netherlands Cancer Institute, Amsterdam, Netherlands.<br /><searchLink fieldCode="AU" term="%22Kapiteijn+E%22">Kapiteijn E</searchLink>; Department of Medical Oncology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands.<br /><searchLink fieldCode="AU" term="%22Welters+MJP%22">Welters MJP</searchLink>; Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Burg+SH%22">van der Burg SH</searchLink>; Medical Oncology, Oncode Institute, Leiden University Medical Center, Leiden, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Houdt+WJ%22">van Houdt WJ</searchLink>; Surgical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+Thienen+JV%22">van Thienen JV</searchLink>; Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands.<br /><searchLink fieldCode="AU" term="%22Haanen+JBAG%22">Haanen JBAG</searchLink>; Medical Oncology, Netherlands Cancer Institute, Amsterdam, Noord-Holland, Netherlands j.haanen@nki.nl.; Department of Medical Oncology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands.<br /><searchLink fieldCode="AU" term="%22van+der+Woude+D%22">van der Woude D</searchLink>; Rheumatology, Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101620585%22">Journal for immunotherapy of cancer</searchLink> [J Immunother Cancer] 2024 Jun 30; Vol. 12 (6). <i>Date of Electronic Publication: </i>2024 Jun 30. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article; Multicenter Study – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22BMJ+Publishing+Group+Ltd%22">BMJ Publishing Group Ltd </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101620585 <i>Publication Model: </i>Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>2051-1426 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2220511426%22">20511426 </searchLink><i>NLM ISO Abbreviation: </i>J Immunother Cancer <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=38945553 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1136/jitc-2024-009215 Languages: – Code: eng Text: English Titles: – TitleFull: Autoantibody-positivity before and seroconversion during treatment with anti-PD-1 is associated with immune-related adverse events in patients with melanoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Borgers JSW – PersonEntity: Name: NameFull: van Wesemael TJ – PersonEntity: Name: NameFull: Gelderman KA – PersonEntity: Name: NameFull: Rispens T – PersonEntity: Name: NameFull: Verdegaal EME – PersonEntity: Name: NameFull: Moes DJAR – PersonEntity: Name: NameFull: Korse CM – PersonEntity: Name: NameFull: Kapiteijn E – PersonEntity: Name: NameFull: Welters MJP – PersonEntity: Name: NameFull: van der Burg SH – PersonEntity: Name: NameFull: van Houdt WJ – PersonEntity: Name: NameFull: van Thienen JV – PersonEntity: Name: NameFull: Haanen JBAG – PersonEntity: Name: NameFull: van der Woude D IsPartOfRelationships: – BibEntity: Dates: – D: 30 M: 06 Text: 2024 Jun 30 Type: published Y: 2024 Identifiers: – Type: issn-electronic Value: 2051-1426 Numbering: – Type: volume Value: 12 – Type: issue Value: 6 Titles: – TitleFull: Journal for immunotherapy of cancer Type: main |
| ResultId | 1 |
